NFA
NVLN

Nationwide Fund Advisors’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Nationwide Fund Advisors’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,311
Closed -$58K – 2773
2017
Q3 		$58K Hold
8,311
– – ﹤0.01% 3026
2017
Q2 		$77K Buy
+8,311
New +$80K ﹤0.01% 2994

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Nationwide Fund Advisors's NVLN Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2017, closing a stake of 8,311 shares — an estimated $58K sold.

Nationwide Fund Advisors first reported a position in NVLN in Q2 2017 and held it in 2 quarters. The position peaked at $77K in Q2 2017. 82 funds tracked by Wall St. Rank hold NVLN as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 8,311 Novelion Therapeutics Inc. Common Shares shares in Q4 2017, an estimated $58K.
  • Nationwide Fund Advisors first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2017 and held it in 2 quarters.
  • Nationwide Fund Advisors's Novelion Therapeutics Inc. Common Shares position peaked at $77K in Q2 2017.
  • 82 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.